عمر بدران

Aug 4, 2026

Neutrophil-to-lymphocyte ratio in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors

Retrospective cohort study evaluating whether baseline neutrophil-to-lymphocyte ratio is associated with CDK4/6 inhibitor-related toxicities and survival outcomes in patients with HR+/HER2− metastatic breast cancer treated with palbociclib or ribociclib.

علم الأورام|אונקולוגיה|Oncology